ClinicalTrials.gg
CompletedNCT01214109Updated Jun 27, 2014Results posted

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

A Phase 1 interventional study of pramipexole extended release and pramipexole extended release in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in China. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

To establish bioequivalence at steady state of:

1)0.375 mg pramipexole extended release tablet q.d. in fasted status versus 0.125 mg pramipexole Immediate release tablet t.i.d. in fasted status 2)1.5 mg pramipexole extended release tablet q.d. in fasted status versus 0.5 mg pramipexole Immediate release tablet t.i.d. in fasted status

To investigate dose proportionality of pharmacokinetics parameters for:

1)pramipexole extended release dosage of 0.375 to 1.5 mg q.d.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria:

  1. Healthy males according to the following criteria:

    Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12-lead , clinical laboratory tests

  2. Age older than or equal 18 and Age younger than or equal 40 years
  3. larger than or equal 19 and Body Mass Index less than or equal 24kg/m2
  4. Signed and dated written prior to admission to the study in accordance with Good Clinical Practice and the local legislation.

Exclusion criteria:

  1. Any finding of the medical examination (including Pulse Rate and electrocardiogram) deviating from normal and of clinical relevance
  2. Any evidence of a concomitant disease
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  4. Surgery of the gastrointestinal tract (except appendectomy)
  5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  6. History of relevant orthostatic hypotension, fainting spells or blackouts.
  7. Chronic or relevant acute infections
  8. History of relevant allergy/ (including allergy to drug or its )
  9. Intake of drugs with a long half-life (longer than 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  10. Use of drugs which might reasonably influence the results of the trial up to 7 days before the start of drug administration in the study or during the study period
  11. Participation in another trial with an drug within one months prior to administration or during the trial
  12. Smoker (more than 10 cigarettes or more than 3 cigars or more than 3 pipes/day)
  13. Inability to refrain from smoking on trial days
  14. Alcohol abuse (more than 40 g/day)
  15. Drug abuse
  16. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  17. Excessive physical activities (within one week prior to administration or during the trial)
  18. Any laboratory value outside the reference range that is of clinical relevance
  19. Any positive results in surface antigen (HBsAg), anti hepatitis B core (HBc) antibodies, anti virus (HCV) antibodies and (HIV) test

    Exclusion criteria specific for this study:

  20. Hypersensitivity to pramipexole or other dopamine agonists
  21. Supine blood pressure at screening of systolic\<100 mmHg and diastolic \< 60 mmHg, or symptomatic orthostatic hypotension (i. .e. clinical symptoms of orthostatic hypotension associated with a decline >=20 mmHg in systolic BP and a decline >=10 mmHg in diastolic BP, at one minute after standing compared to the previous supine systolic and diastolic BP obtained after 5 minutes of quiet rest)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    pramipexole extended release

    0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)

    Drug: pramipexole extended release · Drug: pramipexole immediate release

  • Active comparator
    pramipexole immediate release

    0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)

    Drug: pramipexole extended release · Drug: pramipexole immediate release

Interventions

  • 0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)

  • 0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)

  • 0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)

  • 0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for Pharmacokinetic (PK) Population (All Subjects)

    AUC0-24,ss = area under the plasma concentration-time curve between 0 and 24 hours at steady state. AUCtau,ss = area under the plasma concentration-time curve over a dosing interval at steady state

    Time frame: 27 days

  2. Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for PK Population (Excluding Subjects Due to Emesis)

    AUC0-24,ss = area under the plasma concentration-time curve between 0 and 24 hours at steady state. AUCtau,ss = area under the plasma concentration-time curve over a dosing interval at steady state

    Time frame: 27 days

  3. Maximum Steady State Concentration (Cmax,ss) for PK Population (All Subjects)

    Cmax = maximum observed concentration of the analyte in plasma at steady state

    Time frame: 27 days

  4. Maximum Steady State Concentration (Cmax,ss) for PK Population (Excluding Subjects Due to Emesis)

    Cmax,ss = maximum observed concentration of the analyte in plasma at steady state

    Time frame: 27 days

Secondary outcomes

  1. Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (All Subjects)

    tmax = time of maximum observed plasma concentration

    Time frame: 27 days

  2. Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (Excluding Subjects Due to Emesis)

    tmax = time of maximum observed plasma concentration

    Time frame: 27 days

  3. Peak-to-trough Fluctuation (PTF) for PK Population (All Subjects)

    PTF = Peak-to-trough fluctuation is measured as a percent

    Time frame: 27 days

  4. Peak-to-trough Fluctuation (PTF) for PK Population (Excluding Subjects Due to Emesis)

    PTF = Peak-to-trough fluctuation is measured as a percent

    Time frame: 27 days

  5. Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (All Subjects)

    Cpre,ss = pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose

    Time frame: 27 days

  6. Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (Excluding Subjects Due to Emesis)

    Cpre,ss = pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose

    Time frame: 27 days

  7. Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (All Subjects)

    Cavg = Average concentration of the analyte in plasma at steady state

    Time frame: 27 days

  8. Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (Excluding Subjects Due to Emesis)

    Cavg = Average concentration of the analyte in plasma at steady state

    Time frame: 27 days

  9. Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (All Subjects)

    t1/2,ss - Apparent plasma terminal elimination half-life at steady state

    Time frame: 27 days

  10. Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (Excluding Subjects Due to Emesis)

    t1/2,ss - Apparent plasma terminal elimination half-life at steady state

    Time frame: 27 days

  11. Minimum Steady State Concentration (Cmin,ss) for PK Population (All Subjects)

    Cmin,ss = Minimum observed concentration of the analyte in plasma at steady state

    Time frame: 27 days

  12. Minimum Steady State Concentration (Cmin,ss) for PK Population (Excluding Subjects Due to Emesis)

    Cmin,ss = Minimum observed concentration of the analyte in plasma at steady state

    Time frame: 27 days

  13. The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (All Subjects)

    CL/F,ss = Apparent clearance of the analyte in the plasma at steady state following oral administration

    Time frame: 27 days

  14. The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (Excluding Subjects Due to Emesis)

    CL/F,ss = Apparent clearance of the analyte in the plasma at steady state following oral administration

    Time frame: 27 days

  15. Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (All Subjects)

    Vz/F,ss = Apparent volume of distribution during the terminal phase λz at steady state following oral administration

    Time frame: 27 days

  16. Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (Excluding Subjects Due to Emesis)

    Vz/F,ss = Apparent volume of distribution during the terminal phase λz at steady state following oral administration

    Time frame: 27 days

07

Results

Posted Feb 27, 2012

Participant flow

Participant flow — Overall Study
Milestone0.375 mg q.d.Extended Release (ER)0.125 mg t.i.d. Immediate Release (IR)1.5 mg q.d. ER0.5 mg t.i.d. IR
Started24242424
Completed24242424
Not completed0000

Outcome measures

PrimaryArea Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for Pharmacokinetic (PK) Population (All Subjects)

AUC0-24,ss = area under the plasma concentration-time curve between 0 and 24 hours at steady state. AUCtau,ss = area under the plasma concentration-time curve over a dosing interval at steady state

Time frame:
27 days
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for Pharmacokinetic (PK) Population (All Subjects)
ng*h/mL0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for Pharmacokinetic (PK) Population (All Subjects)6.20 ± 29.77.50 ± 21.519.1 ± 11320.4 ± 104
Statistical analysis
  • 0.375 mg q.d.ER vs 0.125 mg t.i.d. IR · ANOVA · Ratio of geometric least squares means: 82.62 · 90% CI 74.45 to 91.69
  • 1.5 mg q.d. ER vs 0.5 mg t.i.d. IR · ANOVA · Ratio of geometric least squares means: 96.17 · 90% CI 69.33 to 133.42
PrimaryArea Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for PK Population (Excluding Subjects Due to Emesis)

AUC0-24,ss = area under the plasma concentration-time curve between 0 and 24 hours at steady state. AUCtau,ss = area under the plasma concentration-time curve over a dosing interval at steady state

Time frame:
27 days
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for PK Population (Excluding Subjects Due to Emesis)
ng*h/mL0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Area Under the Concentration-time Curve of Pramipexole in Plasma at Steady State Over 24 Hours (AUC0-24,ss); in Case of ER up to the Time Point of Next Dosing (AUCtau,ss) for PK Population (Excluding Subjects Due to Emesis)6.64 ± 19.67.44 ± 22.624.8 ± 34.627.4 ± 40.4
Statistical analysis
  • 0.375 mg q.d.ER vs 0.125 mg t.i.d. IR · ANOVA · Ratio of geometric least squares means: 88.01 · 90% CI 80.76 to 95.92
  • 1.5 mg q.d. ER vs 0.5 mg t.i.d. IR · ANOVA · Ratio of geometric least squares means: 89.37 · 90% CI 81.16 to 98.42
PrimaryMaximum Steady State Concentration (Cmax,ss) for PK Population (All Subjects)

Cmax = maximum observed concentration of the analyte in plasma at steady state

Time frame:
27 days
Reported as:
Geometric mean · ng/mL
Maximum Steady State Concentration (Cmax,ss) for PK Population (All Subjects)
ng/mL0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Maximum Steady State Concentration (Cmax,ss) for PK Population (All Subjects)0.416 ± 25.30.469 ± 22.11.10 ± 1301.20 ± 112
Statistical analysis
  • 0.375 mg q.d.ER vs 0.125 mg t.i.d. IR · ANOVA · Ratio of geometric least squares means: 88.82 · 90% CI 79.89 to 98.76
  • 1.5 mg q.d. ER vs 0.5 mg t.i.d. IR · ANOVA · Ratio of geometric least squares means: 91.97 · 90% CI 60.07 to 140.25
PrimaryMaximum Steady State Concentration (Cmax,ss) for PK Population (Excluding Subjects Due to Emesis)

Cmax,ss = maximum observed concentration of the analyte in plasma at steady state

Time frame:
27 days
Reported as:
Geometric mean · ng/mL
Maximum Steady State Concentration (Cmax,ss) for PK Population (Excluding Subjects Due to Emesis)
ng/mL0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Maximum Steady State Concentration (Cmax,ss) for PK Population (Excluding Subjects Due to Emesis)0.436 ± 20.60.463 ± 22.81.56 ± 26.51.61 ± 42.6
Statistical analysis
  • 0.375 mg q.d.ER vs 0.125 mg t.i.d. IR · ANOVA · Ratio of geometric least squares means: 92.84 · 90% CI 83.8 to 102.86
  • 1.5 mg q.d. ER vs 0.5 mg t.i.d. IR · ANOVA · Ratio of geometric least squares means: 95.05 · 90% CI 84.88 to 106.43
SecondaryTime From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (All Subjects)

tmax = time of maximum observed plasma concentration

Time frame:
27 days
Reported as:
Median · hours
Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (All Subjects)
hours0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (All Subjects)4.00 (0.0 to 8.0)1.00 (0.500 to 2.00)4.00 (0.00 to 8.00)1.00 (0.00 to 2.50)
SecondaryTime From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (Excluding Subjects Due to Emesis)

tmax = time of maximum observed plasma concentration

Time frame:
27 days
Reported as:
Median · hours
Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (Excluding Subjects Due to Emesis)
hours0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Time From Dosing to the Maximum Measured Concentration of the Analyte in Plasma (Tmax) for PK Population (Excluding Subjects Due to Emesis)4.00 (1.00 to 8.00)1.00 (0.500 to 2.00)4.00 (2.00 to 8.00)1.00 (0.500 to 2.00)
SecondaryPeak-to-trough Fluctuation (PTF) for PK Population (All Subjects)

PTF = Peak-to-trough fluctuation is measured as a percent

Time frame:
27 days
Reported as:
Geometric mean · percent
Peak-to-trough Fluctuation (PTF) for PK Population (All Subjects)
percent0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Peak-to-trough Fluctuation (PTF) for PK Population (All Subjects)112 ± 29.486.6 ± 27.5101 ± 33.878.2 ± 34.5
SecondaryPeak-to-trough Fluctuation (PTF) for PK Population (Excluding Subjects Due to Emesis)

PTF = Peak-to-trough fluctuation is measured as a percent

Time frame:
27 days
Reported as:
Geometric mean · percent
Peak-to-trough Fluctuation (PTF) for PK Population (Excluding Subjects Due to Emesis)
percent0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Peak-to-trough Fluctuation (PTF) for PK Population (Excluding Subjects Due to Emesis)109 ± 28.986.2 ± 29.1103 ± 28.382.5 ± 24.8
SecondaryPredose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (All Subjects)

Cpre,ss = pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose

Time frame:
27 days
Reported as:
Geometric mean · ng/mL
Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (All Subjects)
ng/mL0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (All Subjects)NA ± NANA ± NANA ± NA0.507 ± 90.4
SecondaryPredose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (Excluding Subjects Due to Emesis)

Cpre,ss = pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose

Time frame:
27 days
Reported as:
Geometric mean · ng/mL
Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (Excluding Subjects Due to Emesis)
ng/mL0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Predose Steady State Concentration of the Analyte Immediately Before Administration of the Next Drug Administration (Cpre,ss) for PK Population (Excluding Subjects Due to Emesis)NA ± NANA ± NA0.487 ± 1050.616 ± 57.2
SecondaryAverage Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (All Subjects)

Cavg = Average concentration of the analyte in plasma at steady state

Time frame:
27 days
Reported as:
Geometric mean · ng/mL
Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (All Subjects)
ng/mL0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (All Subjects)0.259 ± 29.70.312 ± 21.50.796 ± 1130.848 ± 104
SecondaryAverage Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (Excluding Subjects Due to Emesis)

Cavg = Average concentration of the analyte in plasma at steady state

Time frame:
27 days
Reported as:
Geometric mean · ng/mL
Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (Excluding Subjects Due to Emesis)
ng/mL0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Average Concentration in Plasma Under Steady-state Conditions (Cavg) for PK Population (Excluding Subjects Due to Emesis)0.277 ± 19.60.310 ± 22.61.04 ± 34.61.14 ± 40.4
SecondaryTerminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (All Subjects)

t1/2,ss - Apparent plasma terminal elimination half-life at steady state

Time frame:
27 days
Reported as:
Geometric mean · h
Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (All Subjects)
h0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (All Subjects)13.3 ± 40.77.69 ± 28.614.4 ± 42.88.43 ± 25.3
SecondaryTerminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (Excluding Subjects Due to Emesis)

t1/2,ss - Apparent plasma terminal elimination half-life at steady state

Time frame:
27 days
Reported as:
Geometric mean · h
Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (Excluding Subjects Due to Emesis)
h0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Terminal Half-life of the Analyte in Plasma at Steady State (t1/2,ss) for PK Population (Excluding Subjects Due to Emesis)13.4 ± 42.67.68 ± 30.514.5 ± 46.97.92 ± 16.6
SecondaryMinimum Steady State Concentration (Cmin,ss) for PK Population (All Subjects)

Cmin,ss = Minimum observed concentration of the analyte in plasma at steady state

Time frame:
27 days
Reported as:
Geometric mean · ng/mL
Minimum Steady State Concentration (Cmin,ss) for PK Population (All Subjects)
ng/mL0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Minimum Steady State Concentration (Cmin,ss) for PK Population (All Subjects)NA ± NANA ± NANA ± NA0.478 ± 95.3
SecondaryMinimum Steady State Concentration (Cmin,ss) for PK Population (Excluding Subjects Due to Emesis)

Cmin,ss = Minimum observed concentration of the analyte in plasma at steady state

Time frame:
27 days
Reported as:
Geometric mean · ng/mL
Minimum Steady State Concentration (Cmin,ss) for PK Population (Excluding Subjects Due to Emesis)
ng/mL0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Minimum Steady State Concentration (Cmin,ss) for PK Population (Excluding Subjects Due to Emesis)NA ± NANA ± NA0.403 ± 1020.609 ± 57.2
SecondaryThe Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (All Subjects)

CL/F,ss = Apparent clearance of the analyte in the plasma at steady state following oral administration

Time frame:
27 days
Reported as:
Geometric mean · mL/min
The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (All Subjects)
mL/min0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (All Subjects)1007 ± 29.7833 ± 21.51310 ± 1131228 ± 104
SecondaryThe Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (Excluding Subjects Due to Emesis)

CL/F,ss = Apparent clearance of the analyte in the plasma at steady state following oral administration

Time frame:
27 days
Reported as:
Geometric mean · mL/min
The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (Excluding Subjects Due to Emesis)
mL/min0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
The Apparent Clearance of the Analyte in Plasma at Steady State Following Oral Administration (CL/F,ss) for PK Population (Excluding Subjects Due to Emesis)942 ± 19.6839 ± 22.61008 ± 34.6911 ± 40.4
SecondaryApparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (All Subjects)

Vz/F,ss = Apparent volume of distribution during the terminal phase λz at steady state following oral administration

Time frame:
27 days
Reported as:
Geometric mean · L
Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (All Subjects)
L0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (All Subjects)1167 ± 50.3545 ± 40.61671 ± 135897 ± 138
SecondaryApparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (Excluding Subjects Due to Emesis)

Vz/F,ss = Apparent volume of distribution during the terminal phase λz at steady state following oral administration

Time frame:
27 days
Reported as:
Geometric mean · L
Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (Excluding Subjects Due to Emesis)
L0.375 mg q.d.ER0.125 mg t.i.d. IR1.5 mg q.d. ER0.5 mg t.i.d. IR
Apparent Volume of Distribution During the Terminal Phase at Steady State Following Oral Administration (Vz/F,ss) for PK Population (Excluding Subjects Due to Emesis)1092 ± 47.0547 ± 43.21211 ± 37.8625 ± 45.8

Adverse events

Collected over 27 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.375 mg q.d.ER—0/24 (0%)14/24 (58.3%)
0.75 mg q.d. ER Up-titration—0/24 (0%)9/24 (37.5%)
1.5 mg q.d. ER—0/24 (0%)12/24 (50%)
0.75 mg q.d. ER Down-titration—0/24 (0%)6/24 (25%)
0.375 mg q.d.ER Down-titration—0/24 (0%)0/24 (0%)
0.125 mg t.i.d. IR—0/24 (0%)8/24 (33.3%)
0.5 mg t.i.d. IR—0/24 (0%)14/24 (58.3%)
Most frequent other events
Showing 10 of 15
Most frequent other events
Event0.375 mg q.d.ER0.75 mg q.d. ER Up-titration1.5 mg q.d. ER0.75 mg q.d. ER Down-titration0.375 mg q.d.ER Down-titration0.125 mg t.i.d. IR0.5 mg t.i.d. IR
SomnolenceNervous system disorders1/240/246/240/240/240/245/24
NauseaGastrointestinal disorders2/243/245/240/240/241/246/24
DizzinessNervous system disorders4/243/243/240/240/240/245/24
VomitingGastrointestinal disorders4/241/244/240/240/240/245/24
Blood triglycerides increasedInvestigations5/240/242/242/240/245/242/24
HeadacheNervous system disorders0/244/242/240/240/240/244/24
Abdominal painGastrointestinal disorders0/244/241/240/240/241/241/24
RegurgitationGastrointestinal disorders0/240/240/240/240/240/243/24
Electrocardiogram changeInvestigations1/241/240/243/240/240/240/24
HyperhidrosisSkin and subcutaneous tissue disorders0/243/240/240/240/240/243/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Subjects
Mean31 ± 2.2
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female0
Male24
08

Study locations

1 site
  • 248.665.86002 Boehringer Ingelheim Investigational Site
    Beijing, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010 and a primary completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2010
First posted
Oct 4, 2010
Start
Dec 2010
Primary completionActual
Jan 2011
Results first posted
Feb 27, 2012
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01214109
First posted
Oct 4, 2010
Start date
Dec 2010
Primary completion
Jan 2011
Results posted
Feb 27, 2012
Last update
Jun 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion